FOXM1 and hepatocellular carcinoma: In conclusion, this study revealed that SNRPB promoted HCC progression by modulating the FOXM1-CCNB1 axis and lipid metabolism, indicating its potential as a therapeutic target to augment chemotherapy sensitivity in HCC.